EGFR/ErbB2 signaling pathway has been reported as important target in various kinds of cancer, including breast cancer, head and neck cancer, gastric cancer, pancreatic cancer, colon cancer, renal cell carcinoma, glioblastoma and non-small cell lung cancer, etc [26–37]. This evidence concerns the gene ERBB2 and hereditary clear cell renal cell carcinoma.